在亨廷顿病早期阶段的冷漠和功能状态
Jessie S Gibson1, Kaitlyn R Hay1, Daniel O Claassen1
1University of Virginia School of Nursing, Charlottesville (Gibson, Jiang); Department of Neurology, Vanderbilt University Medical Center, Nashville (Hay, Claassen, McDonell, Brown, Wynn, Isaacs).
The Journal of neuropsychiatry and clinical neurosciences
|November 19, 2024
概括
无动于衷会影响亨廷顿病 (HD) 的功能状态. 解决冷漠症可以改善早期HD患者的生活质量和幸福感.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 漠不关心是亨廷顿病 (HD) 的普遍且具有挑战性的症状.
- 了解无动于衷对功能状态的影响对于HD临床试验至关重要.
- 有限的研究存在于无动于衷的相关物和早期HD的效果.
研究的目的:
- 为了确定与HD患者的冷漠相关的因素.
- 为了确定无动于衷对功能状态的影响,主要在早期的HD样本中.
主要方法:
- 对现有临床的HD数据进行二次分析.
- 斯皮尔曼相关性用于评估冷漠,临床变量和结果之间的关系.
- 多重回归分析,以评估冷漠对功能状态指标的影响 (AFAB,TFC).
主要成果:
- 漠不关心与较低的生活质量相关 (神经质量:对社会角色和活动的满意度,积极影响和福祉).
- 漠不关心的得分与两个功能状态测量 (AFAB,TFC) 有显著的关联.
- 在回归模型中,冷漠解释了功能状态的显著变化.
结论:
- 在HD患者中,冷漠显著影响功能状态,社会满意度和幸福感.
- 准无动于衷对于改善早期HD患者的治疗结果至关重要.
- 在疾病管理中需要进一步的研究和干预措施来解决冷漠.
相关概念视频
Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482


